Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q2 2013 · 10-Q
Revenue—
Net Income-$4.92M-$4.92Mno prior Q2 2012 on file EPS Diluted-$0.41-$0.41no prior Q2 2012 on file Operating Income-$4,984,902— The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
ended Jun 30, 2013 · filed Jul 24, 2013 · 24 d after period end